Levadex, formerly known as MAP0004, is a new formulation of DHE (dihydroergotamine). Researchers said it has been shown more effective than placebo in treating the pain, sensitivity to light and sound and nausea experienced by migraineurs. It was also shown to be fast acting and long lasting.
Levadex could prove to be an important alternative to triptans for people who cannot take them.
DHE is currently available by IV in a clinic or hospital, by intramuscular injections that patients can self administer at home or a nasal spray called Migranal. Having a more accessible, user friendly delivery method that avoids the stomach available will likely be helpful to many migraineurs.
The company developing the medication, MAP Pharmaceuticals, declined to share when they might be applying for FDA approval.
MAP Pharma Soars on Positive Migraine Drug Study
MAP Pharmaceuticals Phase 3 Trial of Levadex Migraine Product Candidate Meets All Four Primary Endpoints
Inhaled DHE Offers Advantages Over IV DHE
Technorati Tags: depression, migraines, chronic illness, health, somebody heal me
Subscribe to the Somebody Heal Me feed: Subscribe in a reader or subscribe by e-mail.
Content by Diana E. Lee.